CA3177277A1 - Methods of use of t-type calcium channel modulators - Google Patents
Methods of use of t-type calcium channel modulators Download PDFInfo
- Publication number
- CA3177277A1 CA3177277A1 CA3177277A CA3177277A CA3177277A1 CA 3177277 A1 CA3177277 A1 CA 3177277A1 CA 3177277 A CA3177277 A CA 3177277A CA 3177277 A CA3177277 A CA 3177277A CA 3177277 A1 CA3177277 A1 CA 3177277A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- compound
- subject
- period
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transmitters (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017140P | 2020-04-29 | 2020-04-29 | |
| US63/017,140 | 2020-04-29 | ||
| US202063050410P | 2020-07-10 | 2020-07-10 | |
| US63/050,410 | 2020-07-10 | ||
| US202063082946P | 2020-09-24 | 2020-09-24 | |
| US63/082,946 | 2020-09-24 | ||
| PCT/US2021/029539 WO2021222342A1 (en) | 2020-04-29 | 2021-04-28 | Methods of use of t-type calcium channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3177277A1 true CA3177277A1 (en) | 2021-11-04 |
Family
ID=78373913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3177277A Pending CA3177277A1 (en) | 2020-04-29 | 2021-04-28 | Methods of use of t-type calcium channel modulators |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230165847A1 (https=) |
| EP (1) | EP4142764A4 (https=) |
| JP (1) | JP2023524039A (https=) |
| KR (1) | KR20230018384A (https=) |
| CN (1) | CN115776894A (https=) |
| AU (1) | AU2021263804A1 (https=) |
| BR (1) | BR112022021946A2 (https=) |
| CA (1) | CA3177277A1 (https=) |
| IL (1) | IL297642A (https=) |
| MX (1) | MX2022013595A (https=) |
| WO (1) | WO2021222342A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3996746A4 (en) | 2019-07-11 | 2023-08-23 | Praxis Precision Medicines, Inc. | T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF |
| US20250170114A1 (en) * | 2022-02-03 | 2025-05-29 | Praxis Precision Medicines, Inc. | Methods of treatment using t-type calcium channel modulators |
| WO2023192885A2 (en) * | 2022-03-28 | 2023-10-05 | Praxis Precision Medicines, Inc. | Methods of using oligomeric compounds to treat scn2a-related disorders |
| US20250295646A1 (en) * | 2022-05-09 | 2025-09-25 | Praxis Precision Medicines, Inc. | Methods of use of t-type calcium channel modulators |
| AU2024229946A1 (en) * | 2023-03-02 | 2025-09-11 | Praxis Precision Medicines, Inc. | Crystalline salts of a t-type calcium channel modulator and methods of use thereof |
| CN121127456A (zh) * | 2023-03-02 | 2025-12-12 | 普拉西斯精密医药公司 | N-((1-(2-(叔丁基氨基)-2-氧代乙基)哌啶-4-基)甲基)-3-氯-5-氟苯甲酰胺的结晶盐形式和其使用方法 |
| WO2025188619A1 (en) * | 2024-03-04 | 2025-09-12 | Praxis Precision Medicines, Inc. | Methods of treating parkinson's disease with t-type calcium channel modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377968B2 (en) * | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| DK3364993T3 (da) * | 2015-10-22 | 2023-01-09 | Cavion Inc | Fremgangsmåder til behandling af angelman syndrom |
| EP3340988B1 (en) * | 2015-11-12 | 2025-04-09 | Afasci, Inc. | Ion channel inhibitory compounds, pharmaceutical formulations and uses |
| MX388586B (es) * | 2016-12-16 | 2025-03-20 | Idorsia Pharmaceuticals Ltd | Combinacion farmaceutica que comprende un bloqueador del canal de calcio de tipo t. |
| WO2018118101A1 (en) * | 2016-12-21 | 2018-06-28 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| MY204493A (en) * | 2017-11-10 | 2024-08-30 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disorders |
| TWI879741B (zh) * | 2018-10-03 | 2025-04-11 | 美商卡凡恩公司 | 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫 |
| EP3996746A4 (en) * | 2019-07-11 | 2023-08-23 | Praxis Precision Medicines, Inc. | T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF |
| US20250295646A1 (en) * | 2022-05-09 | 2025-09-25 | Praxis Precision Medicines, Inc. | Methods of use of t-type calcium channel modulators |
-
2021
- 2021-04-28 IL IL297642A patent/IL297642A/en unknown
- 2021-04-28 JP JP2022566066A patent/JP2023524039A/ja active Pending
- 2021-04-28 WO PCT/US2021/029539 patent/WO2021222342A1/en not_active Ceased
- 2021-04-28 EP EP21795254.8A patent/EP4142764A4/en active Pending
- 2021-04-28 CA CA3177277A patent/CA3177277A1/en active Pending
- 2021-04-28 CN CN202180046763.8A patent/CN115776894A/zh active Pending
- 2021-04-28 MX MX2022013595A patent/MX2022013595A/es unknown
- 2021-04-28 AU AU2021263804A patent/AU2021263804A1/en active Pending
- 2021-04-28 BR BR112022021946A patent/BR112022021946A2/pt unknown
- 2021-04-28 KR KR1020227041859A patent/KR20230018384A/ko active Pending
-
2022
- 2022-10-27 US US17/975,457 patent/US20230165847A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230018384A (ko) | 2023-02-07 |
| EP4142764A4 (en) | 2024-05-29 |
| MX2022013595A (es) | 2023-01-24 |
| AU2021263804A1 (en) | 2023-01-19 |
| BR112022021946A2 (pt) | 2023-01-17 |
| JP2023524039A (ja) | 2023-06-08 |
| EP4142764A1 (en) | 2023-03-08 |
| IL297642A (en) | 2022-12-01 |
| WO2021222342A1 (en) | 2021-11-04 |
| US20230165847A1 (en) | 2023-06-01 |
| CN115776894A (zh) | 2023-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12077502B2 (en) | Formulations of T-type calcium channel modulators and methods of use thereof | |
| US20230165847A1 (en) | Methods of use of t-type calcium channel modulators | |
| US20250295646A1 (en) | Methods of use of t-type calcium channel modulators | |
| AU2023216271A1 (en) | Methods of treatment using t-type calcium channel modulators | |
| US20250375380A1 (en) | High strength single unit dose formulations and methods of use thereof | |
| EP4673220A1 (en) | Crystalline salts of a t-type calcium channel modulator and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250418 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250418 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250428 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250428 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250502 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250711 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250711 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250711 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250711 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260309 |